GeneDx Holdings Corp.
Rank #49HypergrowthWGSWW · Nasdaq
GeneDx Holdings Corp. (WGSWW) — Rank #49 by gross profitability (GP/assets 0.62) · ROE -8.6% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0001818331 · all metrics point-in-time as of the filing date.
About
GeneDx Holdings Corp., a genomics company, provides genetic testing services.
Show moreShow less
The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp.
was founded in 2000 and is headquartered in Stamford, Connecticut.
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- genedx.com
Company Snapshot
P/S is the primary valuation lens — earnings are reinvested, not available for P/E.
Market Cap
—
P/E (annual)
—
P/S (annual)
—
P/B
—
P/OCF (annual)
—
Shareholder Yield
—
Employees
1,300
Industry
Exchange
Nasdaq
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passTerry Smith quality gate
Passes 1/5 Terry Smith thresholds2 of 5 thresholds not computable from filed data.
Earnings bubble check
Current margins may be above sustainable levels — a P/E based on peak earnings can overstate cheapness.
Disclosure regression check
A previously-disclosed line item is no longer reported. Worth checking the filing for why.
Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.62
Primary signal (Novy-Marx).
2nd of 8 SIC 80 peers
Return on equity
-8.6%
Gross margin
69.7%
2nd of 8 SIC 80 peers
Revenue growth (YoY)
40.0%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
22.1%
Revenue CAGR (5Y)
19.0%
Earnings CAGR (3Y)
—
FCF CAGR (3Y)
—
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.97
4th of 7 SIC 80 peers (best = lowest)
Current ratio
3.30×
3rd of 8 SIC 80 peers
Quick ratio
2.90×
Net cash
$35.71M
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$14.26M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
1.68
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
7.5%
Stock-based comp intensity.
Piotroski F-Score
F-Score
6 / 9
Fundamental-strength score (0-9).